TFF Pharmaceuticals, Inc. financial data

Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 20 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 158% % -85%
Debt-to-equity 58% % 606%
Return On Equity -310% % -113%
Return On Assets -196% % -45%
Operating Margin -1611% % 37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,443,041 shares
Common Stock, Shares, Outstanding 3,538,248 shares -94%
Common Stock, Value, Issued $3,538 USD -94%
Weighted Average Number of Shares Outstanding, Basic 4,372,458 shares 130%
Weighted Average Number of Shares Outstanding, Diluted 4,372,458 shares 130%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,161,210 USD 25%
Research and Development Expense $10,812,955 USD -18%
General and Administrative Expense $9,052,449 USD -22%
Operating Income (Loss) $18,704,194 USD 22%
Nonoperating Income (Expense) $182,482 USD 246%
Net Income (Loss) Attributable to Parent $18,521,712 USD 22%
Earnings Per Share, Basic -6 USD/shares 84%
Earnings Per Share, Diluted -6 USD/shares 84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,600,000 USD -73%
Assets, Current $3,508,469 USD -68%
Property, Plant and Equipment, Net $1,639,526 USD -21%
Operating Lease, Right-of-Use Asset $57,990 USD -58%
Other Assets, Noncurrent $95,322 USD 1140%
Assets $7,078,053 USD -52%
Accounts Payable, Current $1,644,361 USD 67%
Accrued Liabilities, Current $1,993,355 USD
Contract with Customer, Liability, Current $250,698 USD
Liabilities, Current $3,940,817 USD 245%
Operating Lease, Liability, Noncurrent $10,856 USD -88%
Liabilities $3,940,817 USD 230%
Accumulated Other Comprehensive Income (Loss), Net of Tax $166,647 USD 18%
Retained Earnings (Accumulated Deficit) $132,090,951 USD -16%
Stockholders' Equity Attributable to Parent $3,137,236 USD -77%
Liabilities and Equity $7,078,053 USD -52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,144,266 USD 28%
Net Cash Provided by (Used in) Financing Activities $901,139 USD
Common Stock, Shares Authorized 180,000,000 shares 100%
Common Stock, Shares, Issued 3,538,248 shares -94%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,266,183 USD 48%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,606,502 USD -73%
Interest Paid, Excluding Capitalized Interest, Operating Activities $15,325 USD
Operating Lease, Liability $52,403 USD -61%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $18,484,647 USD 21%
Lessee, Operating Lease, Liability, to be Paid $53,813 USD
Operating Lease, Liability, Current $52,403 USD -37%
Lessee, Operating Lease, Liability, to be Paid, Year One $38,438 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,410 USD
Operating Lease, Payments $22,275 USD 3.7%
Depreciation, Depletion and Amortization $140,183 USD 14%
Share-based Payment Arrangement, Expense $567,672 USD -26%
Interest Expense $15,614 USD